Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
Lund University researchers discovered 'main switch' that regulates cell invaginations

Lund University researchers discovered 'main switch' that regulates cell invaginations

Cardiome Pharma reports net loss of $7.4 million in second quarter 2015

Cardiome Pharma reports net loss of $7.4 million in second quarter 2015

Cryptogenic stroke frequent and recurrent

Cryptogenic stroke frequent and recurrent

Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Six hot line sessions set to reveal latest research in cardiovascular disease at ESC Congress 2015

Six hot line sessions set to reveal latest research in cardiovascular disease at ESC Congress 2015

More people turn to popular new blood thinners for atrial fibrillation treatment

More people turn to popular new blood thinners for atrial fibrillation treatment

TTP’s elastography imaging technology provides vital diagnostic information during surgery

TTP’s elastography imaging technology provides vital diagnostic information during surgery

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

WATCHMAN Device helps reduce stroke risk, stop use of blood thinners in patients with atrial fibrillation

WATCHMAN Device helps reduce stroke risk, stop use of blood thinners in patients with atrial fibrillation

Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Uninterrupted NOAC treatment during catheter ablation of atrial fibrillation is safe, shows research

Uninterrupted NOAC treatment during catheter ablation of atrial fibrillation is safe, shows research

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

Stanford researchers find how neurons work together to control movement in people with paralysis

Stanford researchers find how neurons work together to control movement in people with paralysis

Statins benefit patients undergoing major lung resection, lower major complications

Statins benefit patients undergoing major lung resection, lower major complications

Atrial fibrillation patients who stop blood thinners before elective surgery have less risk of major bleeding

Atrial fibrillation patients who stop blood thinners before elective surgery have less risk of major bleeding

AliveCor Mobile ECG now available in Canada

AliveCor Mobile ECG now available in Canada

Scientists develop computational method to study link between birth month and disease risk

Scientists develop computational method to study link between birth month and disease risk

Ibrutinib shows promise in CLL/SLL

Ibrutinib shows promise in CLL/SLL

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.